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Background: Cardiovascular disease is a major cause of mortality and morbidity and its prevalence is set to
increase. While the benefits of medical and lifestyle interventions are established, the effectiveness of interventions
which seek to improve the way preventive care is delivered in general practice is less so. The aim was to study and
to compare the effectiveness of 2 intervention programmes for reducing cardiovascular risk factors within general
practice.
Methods: A randomised controlled trial was conducted in Belgium between 2007-2010 with 314 highly educated
and mainly healthy professionals allocated to a medical (MP) or a medical + lifestyle (MLP) programme. The MP
consisted of medical assessments (screening and follow-up) and the MLP added a tailored lifestyle change
programme (web-based and individual coaching) to the MP. Primary outcomes were total cholesterol, blood
pressure, and body mass index (BMI). The secondary outcomes were smoking status, fitness-score, and total
cardiovascular risk.
Results: The mean age was 41 years, 95 (32%) participants were female, 7 had a personal cardiovascular event in
their medical history and 3 had diabetes. There were no significant differences found between MP and MLP in
primary or secondary outcomes. In both study conditions decreases of cholesterol, systolic blood pressure, and
diastolic blood pressure were found. Unfavourable increases were found for BMI (p < .05). A significant decrease of
the overall cardiovascular risk was reported (p < .001).
Conclusions: Both interventions are effective in reducing cardiovascular risk. In our population the combined
medical and lifestyle programme was not superior to the medical programme.
Trial Registration: ISRCTN23940498
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Cardiovascular disease (CVD) is a major cause of mortal-
ity and morbidity in industrialized countries and is ac-
countable for high societal costs [1]. Because of the severe
disease burden, preventive actions are perceived as a* Correspondence: neree.claes@uhasselt.be
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reproduction in any medium, provided the ormajor public health priority. These actions are important,
knowing that the contribution of preventable risk factors
is 70-76% for the total number of CVD [2].
In order to lower CVD, preventive programmes should
focus both on medical (cholesterol, blood pressure, gly-
caemia) and lifestyle risk factors (smoking, low levels of
physical activity, and unhealthy diet) [2]. Scientific evi-
dence suggests that such programmes have favourable
effects on cardiovascular (CV) risk factors [3-5]. Those
programs and interventions are delivered by primary care
providers (ea. trained nurses, dieticians, physiotherapist)td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tioners. Literature review learned that the implementation
of such programmes is rarely studied within general prac-
tice [6]. However disappointing follow-up of patient with
CV risk factors in primary care - recently found in the
Euroaspire survey - stressed out the urge to study the im-
plementation of CV prevention programmes within general
practice. Organisation of such preventive programmes has
to be based on clinical guidelines and its implementation
has to be done in line with Buckley’s criteria for general
practice (recall of patients, systematically monitoring of risk
factors and medication, patient and general practitioner
education) (Figure 1) [7,8]. Those models and their imple-
mentation have not been studied on their effectiveness in
general practice.
Our first aim was to study the effectiveness of two CV
prevention programmes for reducing cardiovascular risk
factors for highly educated professionals within general
practice. Both programmes are based on the European
guidelines for CV. Our second aim was to implement
two prevention models feasible for general practice and
based on Buckley’s implementation factors. The imple-
mentation of such programmes on a larger scale will be
discussed in detail at the end of this paper.
Methods
Participants
PreCardio was a randomised clinical trial with a follow-
up of 3 years [9]. The inclusion criteria for participants
were age between 25–75 years and being insured by the
‘De Onderlinge Ziekenkas’ and living in the province of
Limburg. All of the insured were self-employed lawyers.Figure 1 Guidelines for cardiovascular prevention.This led to the selection of a highly educated and rela-
tively healthy group of professionals participating in the
study. This is a general sample of an active group of pro-
fessionals. The selection of this specific group of profes-
sionals, namely self-employed lawyers, was because of to
the good organisation of this professional group which is
adequate to disseminate information on the study in an
efficient way. All study participants signed an informed
consent and had access to the internet. No other eligibil-
ity criteria were used. Study recruitment took place
between February and April 2007. Potential participants
(n = 737) were invited through an active recruitment
strategy within the Bar (=professional organizations of
lawyers): the president of the bar was informed on the
study by the study-coordinator, secondly the study was
presented at the board of directors, after their positive
advice every director committed to convince 25 lawyers
to participate. Supplementary, a letter from the study
secretary with an invitation from the head of the lawyers
was sent with the request to participate and to sign an
informed consent. Three-hundred fourteen adults signed
an informed consent to participate (42%). The study
participants were randomized using a nonstratified
randomization technique with a known probability. Each
participant had a 67% chance to be allocated to the
intervention group. The randomisation was performed
by an independent person. The names of the partici-
pants were written on papers that were put in sealed en-
velopes. Next, the envelopes were randomly assigned by
hand to two baskets for the intervention and the control
group, respectively, with a ratio of 2/1. It was no blind
randomisation. One hundred six participants were
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participants of the MP and 13 of the MLP chose not to
start the study despite prior consent, resulting in 295
participants at the start of the study. The participant
flow chart is shown in Figure 2. Of these participants
68% were male, the mean age was 41 years, the mean
systolic blood pressure was 131 mmHg and the mean
diastolic blood pressure was 84 mmHg. The mean chol-
esterol of the participants was 188 mg/dl, the mean body
mass index (BMI) was 25 kg/m2 and 18% were smokers.
Approval was obtained from the ethics committee of
Hasselt University and the study was registered
(ISRCTN23940498).
Interventions
Participants in both prevention programmes (MP+
MLP) were invited for a baseline multidisciplinary pre-
vention consultation at Hasselt University, consisting
of a medical screening by a general practitioner (GP)
(anamnesis, blood pressure, cholesterolaemia, gly-
caemia), a dietician consult (weight, length and fat per-
centage), an assessment of physical fitness (step test) and
a consult by a psychologist [9]. Patients were classified
in the pre-contemplation, contemplation, preparation,
action or maintenance stage [10]. After this screening all
the participants received a printed profile with their36 months
baseline
Figure 2 Study flow.individual risk factors and total cardiovascular risk [11].
This printed profile also contained advices to improve
lifestyle factors based on all the results of the assess-
ment. Participants with an aberrant medical risk factor
(high blood pressure, hypercholesterelaemia or -
glycaemia) and a high total risk were referred to their
GP for immediate follow-up. Participants with a medium
risk were advised to consult their GP every year, those
with low risk, once every three year. The GPs of the par-
ticipants were educated during a 4 hours training and
had access to an online education tool for CVD prevention.
An electronic risk calculator was developed and integrated
in the electronic medical file of the GPs (n = 240) [12]. Sup-
plementary a copy of the participants printed profile was
sent to their GP. The multidisciplinary screening consulta-
tions were organised yearly at the University during the
study. Participants of the MLP received additional interven-
tions based on their personal scores for behavioural (phys-
ical activity, nutrition, smoking) variables [13-15].
Participants received access to a personalised website and
one-on-one coaching. The personalised website included
tailored advices based on the variables mentioned above.
The one-on-one coaching targeted one or multiple behav-
iours based on the preferences of the individual. The
coaching was delivered by a health psychologist in collabor-
ation with a general practitioner, a physiotherapist, a
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selling. The coaching could be delivered by regular mail, e-
mail, telephone, face-to-face (individual or group). Partici-
pants could freely determine the intensity and delivery mode
of the MLP [16].
Power calculation
A power calculation was performed to determine the
number of study participants needed to detect a signifi-
cant effect between the both programmes with a power
of 80%. The sample calculation was based on the popu-
lation standard deviation of the primary outcome meas-
ure. For our study this was the systolic blood pressure
(SBP). Kelly et al. found a mean SBP of 125 mmHg (SD
14) [17]. The sample size calculation was performed
with Nquery Advisor 4.0®. A two group t-test with a 0.05
two-sided significance level would have 80% power to
detect the difference between the MP mean of
125 mmHg and the MLP mean of 120 mmHg. Assuming
a common standard deviation of 14 mmHg, a total sam-
ple size of 282, 93 in the MP and 186 in the MLP would
be sufficient.
Outcome measures
The aim of this randomised trial was to examine the ef-
fectiveness of two cardiovascular prevention programmes
in reducing cardiovascular risk factors within primary care
with 3 years of intervention (April 2007-April 2010). The
primary outcomes were systolic and diastolic blood pres-
sure, total cholesterol, weight, and body mass index. These
outcome measures were determined by general practi-
tioners, assisted by nurse practitioners during large-scale
screening events at the university or at the workplace of
the participants. The secondary outcomes were smoking,
physical fitness, stages of behaviour change, medication
use, and total cardiovascular risk. Blood pressure was
measured with an Omron X6®. Total cholesterol was
measured using capillary blood with an Accutrend Plus
system®, weight and body fat was measured with a Tanita
TBF-300A Body Composition Analyzer®. Body mass index
(BMI) is body weight (kg) divided by the square of the
height (m). Smoking was questioned using a short ques-
tionnaire from a national health questionnaire [18]. Phys-
ical fitness was tested with a step test, stepping up and
down a platform (90 beats steps per minute) during 5 mi-
nutes [19]. Heart rate was recorded 1, 2 and 3 minutes
after completing the step test in sitting position. Physical
fitness level was calculated with the formula: 30.000 di-
vided by 2 times the sum of the three recuperation hart
rates. This continuous variable is transformed to a cat-
egorical variable that represents the fitness category as fol-
lows: < 55 (low); 55–64,9 (low average); 65–79,9 (high
average); 80–89,9 (good); and > 90 (excellent). Total car-
diovascular risk was determined using the score table,scoring participants with a risk ≥4% to die of an cardiovas-
cular event as a high risk, 2-4% as medium risk and <2%
as low risk [11]. The stages of behaviour change were
measured using a single table for assessing physical activ-
ity, diet and quitting smoking [9]. For diet, for instance, a
clear description of the dietary behaviour targeted was in-
cluded in the questionnaire, namely: eating a low fat diet
and 5 portions of fruit and vegetables daily.
Statistical analyses
Repeated measures ANOVAs were used to examine time
and time x study condition interaction effects. A p-level
lower than 0.05 was considered to be significant. Evolu-
tions of stages of change in the two study conditions
were compared using Chi square analyses. All analyses
were performed with SPSS 16.0.
Results
Participants
Overall 314 participants signed in to participate the
study, 295 of these group underwent the multidisciplin-
ary prevention consultation and were included (Figure 2).
The mean age was 40.73 years (SD 10.54), 95 (32%) par-
ticipants were female, 7 had a personal cardiovascular
event in their personal history and 3 had diabetes
(Table 1). There were no significant differences in base-
line characteristics between MP and MLP except for
smoking (21% in the MLP versus 11% in the MP arm,
p < 0.05). Forty participants (13%) dropped out of the
study prior to reaching the endpoint of the study. The
main reason to stop was lack of time (n = 20); only inter-
est in MP (n = 7), stopped as lawyer (n = 7) and disap-
pointment in the study tools (n = 6). No one of the
drop-outs had had a cardiovascular event. Contact was
lost with 10 participants. There was no significant differ-
ence in drop-outs between the two study conditions.
Participants who dropped out were significantly younger
(p < 0.05), female (p < 0.05), without a family history of
cardiovascular events (p < 0.05), having a significant
lower BMI (p < 0.05) and lower daily unsaturated fat in-
take (p < 0.05). In total 255 participants (87%) completed
the 3-year study.
Effectiveness of the cardiovascular prevention
programmes
Among the study completers, a decrease in total choles-
terol (p < 0.001), systolic blood pressure (p < 0.01), and
diastolic blood pressure (p < 0.001) in both study condi-
tions was found (Table 2). There was a significant in-
crease in BMI (p < 0.01). Overall, there was a decrease in
the fitness-score. Overall, the average fitness category
was low average at the start of the study, and low at the
end of the study. Most importantly, there was a signifi-
cant decrease of total cardiovascular risk (p < 0.001).
Table 1 Baseline characteristics of the study population
Baseline characteristics Total (n = 295) MP (n = 100) MLP (n = 195) P-value difference between groups
Gender (%)
Male 200 (68) 67 (67) 133 (68) 0.83
Female 95 (32) 33 (33) (62) (32)
Mean age (y) (SD) 40.73 (10.54) 40.03 (10.57) 41.09 (10.54) 0.42
Mean systolic blood pressure (mmHg) (SD) 130.57 (19.87) 131.04 (18.96) 130.33 (20.36) 0.77
Mean diastolic blood pressure (mmHg) (SD) 83.76 (11.15) 84.12 (11.41) 83.58 (11.04) 0.69
Mean total cholesterol (mg/dl) (SD) 187.93 (30.66) 189.91 (32.60) 186.96 (29.65) 0.45
Mean body mass index (kg/m2) (SD) 24.95 (3.97) 24.92 (3.84) 24.97 (4.04) 0.93
Personal cardiovascular event (%) 7 (2) 4 (4) 3 (1.5) 0.19
Diabetes (%) 3 (1) 1 (1) 2 (1) 0.98
Smokers (%) 52 (18) 11 (11) 41 (21) 0.03
Mean physical fitness (SD) 55.34 (11.76) 54.97 (11.98) 55.54 (11.67) 0.72
Mean overall cardiovascular risk (SD) 0.01 (0.02) 0.01 (0.02) 0.01 (0.02) 0.89
MP Medical Program, MLP Medical + Lifestyle programme, SD standard deviation.
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a cardiovascular event. And one patient was diagnosed
with diabetes in the MLP. There were no significant dif-
ferences found between MP and MLP in blood pressure,
cholesterolemia, BMI and Physical fitness (Table 2). At
baseline, 48 participants (19%) were smoker compared
to 29 (11%) at the study endpoint. The proportion of
smoking cessation in the total sample was 44%. The
proportion of smoking cessation in the MP (6/10 or
60%) versus the MLP (15/38 or 39.5%) was not statisti-
cally different.
Medication use
A categorical variable was used for medication use with
4 possibilities: no use of medication, medication use de-
creased, medication use stayed the same, and medication
use increased. Two hundred thirty seven patients used
no medication. In 4 participants medication use de-
creased, in 16 participants the medication use stayed the
same, and in 38 cases medication use increased. An
interaction effect was found for systolic blood pressure
(p < 0.001) and for diastolic blood pressure (p < 0.001)
indicating that these decreases might be due to medica-
tion adherence. At the end of the study, in total, 33 pa-
tients took antihypertensive medication, 18 patients
received anti-platelet medication, 29 used lipid lowering
medication, and 4 patients used diabetes medication.
Evolution of the stages of behaviour change
No significant differences between the MP and MLP in
evolution of the stages of behaviour change at the end-
point was found. In Figure 3 the evolution of the stage
of behaviour change is given for the three behaviours:
smoking cessation, diet and physical activity. For thetotal sample, the only difference from start to endpoint
was found for the categories of change for smoking, not
for physical activity or diet.
Discussion and conclusion
In our population (relatively young and highly educated
professionals) the combined medical and lifestyle
programme (MLP) was not superior to the medical
programme (MP). Both intervention programmes were
effective in reducing medical cardiovascular risk factors
and the overall CVD risk. This is an important finding
given the achievements on a relatively short time period
(3 years).
The MLP was not superior to the MP with regard to
the medical risk factors and also with regard to the
stages of behaviour change. These findings are in line
with several recent reviews suggesting that multiple risk
factor interventions including coaching methods pro-
duce only marginal results when implemented in general
population samples [8]. Additionally, the lack of effect of
the MLP compared to the MP might be due to several
factors. Potential explanations for the lack of interven-
tion effect are: the selection of relatively young and
healthy highly educated professionals (70%), a medical
assessment in both study conditions; the high level of
choice options might have overwhelmed the participants
and led them to select an insufficient intervention dose.
Furthermore, it could be that the participants in the MP
were involved in additional lifestyle programmes inde-
pendent from PreCardio. So our results suggest that an
intensive MLP is of modest value within a highly edu-
cated population sample, an organised MP within pri-
mary care can be sufficient to evoke improvements in
risk factors. Medical screening and feedback on
Table 2 Repeated measures ANOVAs
Total sample (n = 255) Mean
change
Ftime P
values
MP (n = 82) Mean
change
MLP (n = 173) Mean
change
Ftime*condition P
values
Medical risk factor Pre mean
(SD)
Post mean
(SD)
Pre mean
(SD)
Post mean
(SD)
Pre mean
(SD)
Post mean
(SD)
Systolic blood pressure
(mmHg)
131.30
(18.30)
127.55
(16.52)
−3.75 10.71** 0.001 132.33
(19.41)
126.01
(18.75)
−6.32 130.82
(17.79)
128.28
(15.35)
−2.54 1.95 0.164
Diastolic blood pressure
(mmHg)
84.39 (11.38) 79.77 (10.52) −4.62 37.16*** 0.000 85.37 (11.61) 79.15 (8.51) −6.22 83.94 (11.27) 80.06 (11.34) −3.88 1.99 0.159
Total cholesterol (mg/dl) 188.03
(30.79)
180.38
(30.92)
−7.65 15.33*** 0.000 190.00
(33.00)
179.41
(27.61)
−10.59 187.09
(29.72)
180.84
(32.44)
−6.25 1.02 0.314
Body Mass Index (kg/m2) 25.14 (3.99) 25.53 (4.18) 0.39 11.96** 0.001 25.21 (3.85) 25.53 (3.84) 0.32 25.11 (4.07) 25.53 (4.34) 0.42 0.23 0.635
Physical fitness 55.21 (11.13) 53.79 (10.55) −1.42 0.860 0.356 53.70 (8.45) 53.88 (8.95) 0.18 55.83 (12.07) 53.75 (11.20) −2.08 1.22 0.273
Overall CVD risk1 0.011 (0.02) 0.008 (0.01) −0.003 15.68*** 0.000 0.011 (0.020) 0.008 (0.015) −0.004 0.011 (0.015) 0.008 (0.012) −0.002 0.95 0.332
1 Overall CVD risk is the 10-year risk of dying from a cardiovascular event using the SCORE risk tables.
* < .05; ** < .01; *** < .001.
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Figure 3 Stage of behaviour change for the 3 behaviours from baseline to follow-up.
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improvements with regard to risk factors such as choles-
terol and blood pressure for a relatively young and
highly educated sample.
The most important strength of this study was the use
of a randomised design. The second strength is the in-
clusion of a mixed population sample in terms of overall
CVD risk (high, medium and low CVD risk). However,
the study has several limitations. A first limitation is the
participants’ exposure to the lifestyle programme. Partic-
ipants were free to choose the self-determined interven-
tion intensity and the delivery mode of the MLP. This
freedom was theory-inspired but led to some partici-
pants under using the programme which potentially lim-
ited the effect of the MLP. This might explain the lack
of effect on the stages of behaviour change. The partici-
pants of the MLP received a mean intervention time of
22 minutes (SD 18) for diet and 37 minutes (SD 18) for
physical activity [6]. Secondly, the participants were
highly educated volunteers, limiting the generalisability
of our findings. However, it is a general sample of active
professionals and since population-targeted strategies
are advised by the literature it is important to know
which kind of interventions are cost-effective in this
population subgroup. Nevertheless, secondary preven-
tion initiatives are needed to be able to include effective
and cost-effective interventions for people at high risk
for CVD events such as acute coronary syndrome survi-
vors [20]. Given their high motivation to take part in a
cardiovascular prevention programme and their organ-
isational and financial abilities to seek support elsewhere,
it cannot be excluded that people allocated to the MP
sought help to change their behaviour beyond the study
context after receiving a printed profile with their risk
factors.
Effectiveness of prevention programs in general practice?
STUDIES which seek to improve the way preventive
care is delivered in primary care are rather scarce and
diverse (different study design, population andintervention(dose)) [8]. A study with a comparable
population with regard to cardiovascular risk is ‘Hartslag
Limburg’. It was a community based lifestyle programme
to reduce cardiovascular risk factors in a cohort of
5 years [21]. All lifestyle factors improved. ‘Impala’, a
nurse-led intervention study in primary care, didn’t
benefit over the usual care mainly due to a study nurse
detecting risk factors in both study conditions [22]. In
‘Euro action’ a nurse-coordinated, multidisciplinary, fam-
ily based, ambulatory programme was studied [23]. In
this programme healthier lifestyle scores and improved
risk factors were obtained for patients with coronary
heart disease and high risk patients in comparison to
those followed by usual care. A comparable design study
as the PreCardio-trial is the Swedish ‘Björknäs study’
[24]. Our findings are however not in line with their re-
sults: a significant difference comparing usual care and
usual care plus a lifestyle programme. The superiority of
their MLP could be explained by the high intensity of
their lifestyle programme (weekly personal meetings by
default, no self-selection) and patient selection (high
risk). And most important the MP of our study was not
comparable with usual care: it was a new multidisciplin-
ary management model. This needs some explanation
about the organization of USUAL CARE in Belgium.
Until 2011 prevention was not remunerated in Belgium
and prevention was performed exemplary. Usual care
was organised around curative medicine meaning that a
patient consulted a general practitioner only with phys-
ical complaints. GP performed a clinical examination
with/without a blood sample. Based on these findings
therapy was started. No medical or lifestyle prevention
parameters (glycemie, cholesterolaemia, BMI, waist cir-
cumference, physical fitness, food intake, smoking status,
…) were systematically detected nor treated. So primary
prevention (to prevent the occurrence of disease and
promote health) was scarce and secondary prevention
(to prevent the progress of an illness or serious diag-
nosed risk factors) wasn’t organised. Since 1th of April
2011 Belgian government enlarged GP’s tasks with
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ment forgot to define necessary criteria such as practi-
tioner’s conditions & knowledge, goals, management,
coordination of the prevention tasks. The under-
evaluation of prevention is reflected in a disappointing
follow-up of patient with CV risk factors in primary care
(Euroaspire III survey conducted in 12 European coun-
tries) [25]. The results of the European surveys show
that the lifestyle (of coronary and high-risk) patients is a
major cause of concern, with persistent smoking and
high prevalence of both obesity and central obesity.
Blood pressure, lipids and glucose control are inad-
equate, with most patients, not achieving the targets de-
fined in the prevention guidelines. There is considerable
potential throughout Europe to raise the standard of
preventive cardiology through more lifestyle interven-
tion, control of other risk factors, and optimal use of
prophylactic drug therapies. Cardiovascular disease pre-
vention needs a comprehensive, multidisciplinary ap-
proach that addresses lifestyle and risk-factor
management by cardiologists, general practitioners,
nurses and other health professionals, and a healthcare
system that invests in prevention.
Implementation of prevention programmes in general
practice on a large scale?
In most countries there is a need for a management
model to organise prevention within usual care in col-
laboration with the governmental and academic actors.
In such a model different aspects have to be discussed.
The first aspect is the SCREENING. Who will be
screened? A possibility could be to invite all adults be-
tween 40–75 years. It could be expected that in such a
programme about half of the patients without a history
of cardiovascular disease will receive at least one pre-
scription, diet or health advice [26]. To perform the
screening more cost-efficient, routine administrative
data out of the electronic medical file could be used to
invite people after a cardiovascular risk stratification
[27]. In this case only the medium to high risk patient
will be invited. Who will perform the screening? This
could be a multidisciplinary screening consultation with
a GP as prevention coordinator. The prevention coord-
inator sends the results to the treating GP for follow-up.
In case of a multidisciplinary screening, the GPs will
need (supporting) tools: administrative support, know-
ledge, sufficient time with an adequate remuneration, an
electronic risk calculator, point of care testing for
cholesterol-glycaemia, a weight balance and question-
naires on life style. These tools are necessary, it is
already proven that GPs don’t always take time to give
lifestyle advice or treat risk factors sufficiently. The next
aspect is the FOLLOW-UP. Who is going to invite the
patient for follow-up: high risk every 4 months,medium risk yearly and low risk every 3 years? The lat-
ter could be the task of the prevention coordinator in
collaboration with the GP. Who will perform the
follow-up? The follow-up will be performed by the
treating GP (in collaboration with the cardiologist in
case of secondary prevention). Also in the follow-up GPs
will need the same (supporting) tools as mentioned
above. This is in line with the quality improving factors
of Buckley for management models in primary care (e.g.,
recall of patients and systematically monitoring of risk
factors) [8].
This study showed that it is possible to implement a
multidisciplinary management model in routine general
practice with the incorporation of a medical prevention
coordinator to perform the screening and to coordin-
ation. The follow-up can be done by the treating GP.
This management model will improve patient follow-up
regarding their risk factors.
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